NeuroSense Therapeutics (NRSN) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free NRSN Stock Alerts $1.08 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 1:56 AM | msn.comEvaxion Biotech GAAP EPS of $0.03 beats by $0.53, revenue of $0.05MMay 28, 2024 | americanbankingnews.comNeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 0.6%May 25, 2024 | markets.businessinsider.comBuy Rating on Neurosense Therapeutics Backed by Promising ALS Treatment ResultsMay 20, 2024 | prnewswire.comNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitMay 14, 2024 | prnewswire.comNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningMay 7, 2024 | markets.businessinsider.comNeuroSense Reports Positive Data Analysis From PARADIGM Trial With PrimeC In ALSMay 7, 2024 | prnewswire.comNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsMay 2, 2024 | prnewswire.comNeuroSense Announces First Quarter 2024 Business UpdateApril 22, 2024 | finance.yahoo.comNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseApril 19, 2024 | investing.comNeuroSense reports positive ALS trial results, trends in biomarkersApril 18, 2024 | prnewswire.comNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingApril 12, 2024 | finance.yahoo.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | prnewswire.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 10, 2024 | prnewswire.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementApril 9, 2024 | markets.businessinsider.comNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketApril 9, 2024 | prnewswire.comNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsApril 7, 2024 | uk.investing.comNeuroSense reports significant ALS trial results, year-end financialsApril 5, 2024 | investorplace.comNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023April 5, 2024 | finance.yahoo.comNeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateMarch 23, 2024 | morningstar.comNeuroSense Therapeutics Ltd NRSNFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | prnewswire.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 7, 2024 | finance.yahoo.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleJanuary 30, 2024 | finanznachrichten.deNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 9, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsJanuary 4, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementDecember 19, 2023 | investing.comNeurosense Therapeutics (NRSN) Earnings Dates & ReportsDecember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)December 14, 2023 | finance.yahoo.comNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialDecember 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)December 6, 2023 | finance.yahoo.comWe're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn RateDecember 5, 2023 | marketwatch.comNeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares FallDecember 5, 2023 | markets.businessinsider.comNeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary EndpointsDecember 5, 2023 | msn.comNeuroSense ALS candidate meets key study goalsDecember 5, 2023 | finance.yahoo.comNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsDecember 4, 2023 | finance.yahoo.comNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023November 28, 2023 | msn.comNeuroSense Therapeutics GAAP EPS of -$0.67November 28, 2023 | markets.businessinsider.comNeuroSense Therapeutics 9-Month Loss NarrowsNovember 28, 2023 | finance.yahoo.comNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | markets.businessinsider.comNeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS TreatmentNovember 13, 2023 | finance.yahoo.comNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNovember 6, 2023 | finance.yahoo.comNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023November 1, 2023 | finance.yahoo.comNeuroSense Therapeutics to Participate in BIO-Europe FallOctober 19, 2023 | finance.yahoo.comRenowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeCOctober 19, 2023 | marketbeat.comTrading was temporarily halted for "NRSN" at 10:10 AM with a stated reason of "LULD pause."October 19, 2023 | marketbeat.comTrading was temporarily halted for "NRSN" at 10:10 AM with a stated reason of "LULD pause."October 17, 2023 | finance.yahoo.comNeuroSense CEO Provides Q3 2023 UpdateOctober 4, 2023 | finance.yahoo.comNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelSeptember 25, 2023 | barrons.comNeuroSense Therapeutics Ltd. Wt Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… NRSN Media Mentions By Week NRSN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼0.680.79▲Average Medical News Sentiment NRSN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼31▲NRSN Articles Average Week Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CALC News Today LPTX News Today RPHM News Today BLRX News Today CARM News Today RMTI News Today AEON News Today ANEB News Today THAR News Today KZR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.